Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis

BACKGROUND: The risk of symptomatic intracranial haemorrhage (sICH) after thrombolysis is low but severe. Lower dose of alteplase may reduce the risk of sICH. We aim to identify subsets of patients who could benefit from lower dose of alteplase compared with standard dose. METHODS: Data from two obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yi, Han, Ye, Shen, Haipeng, Wang, Yilong, Ma, Frank, Li, Hao, Wang, Yongjun, Dong, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804063/
https://www.ncbi.nlm.nih.gov/pubmed/32611728
http://dx.doi.org/10.1136/svn-2020-000388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804063/
https://www.ncbi.nlm.nih.gov/pubmed/32611728
http://dx.doi.org/10.1136/svn-2020-000388

Ejemplares similares